Navarra

Quiénes somos

  • 9 de enero de 2024
    Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008)
  • diciembre 8, 2022
    A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
  • 23 de mayo de 2022
    Sotorasib y panitumumab frente a la elección del investigador para participantes con sarcoma de rata de Kirsten (KRAS) con mutación p.G12C (CodeBreak 300)
  • 5 de abril de 2022
    A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)
  • 5 de abril de 2022
    A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
  • 5 de abril de 2022
    A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
  • 5 de abril de 2022
    Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors